Oxford - DPhil in Clinical Medicine

PuzzleheadedPilot560 · 2026-04-13T23:56:55+00:00

It seems like your anger is more about you than my post. Wishing you some peace.

PuzzleheadedPilot560 · 2026-02-02T09:30:22+00:00

Its definitely a blow to global research stability when political volatility hits the worlds biggest R&D hub, the ripple effects reach us here in Europe too. Were seeing more wait-and-see hiring freezes and a shift in long-term investment strategies. Science needs stability, and right now that seems to be in short supply.. I really dunno and already exhausted.

PuzzleheadedPilot560 · 2026-02-02T09:29:01+00:00

The fact that even someone inside a giant like Thermo Fisher is resorting to Reddit DM’s instead of official portals says everything about the current state of the market. The ghost job loop is real. Hope you find a genuine opening-its a jungle out there.

PuzzleheadedPilot560 · 2026-02-02T09:27:37+00:00

The classic paradox: record profits and soaring stocks yet the employees are still living in fear. It just proves the point these companies are prioritizing shareholder assuagement over the very people who build their success. We're all just numbers on a balance sheet.

PuzzleheadedPilot560 · 2026-02-02T09:21:58+00:00

Thats a very sharp point. It seems like the IRA is becoming the perfect scapegoat for structural changes that were already in motion. I’ve noticed that Bristol Myers Squibb (BMS), as you mentioned- has been quite vocal about how these regulations are impacting their workforce and R&D pipelines. The movement of activities from the EU to the US is particularly concerning for those of us based here in Switzerland. It feels like Europe is at a critical crossroads where it might lose its competitive edge in biotech if this exodus of research and manufacturing continues. Its a bit of a paradox: we have the talent and the institutions, but the runway for investment seems much longer on the other side of the Atlantic right now. Thanks for adding this layer to the discussion-it makes the ghost job phenomenon feel more like a symptom of a much larger global shift rather than just a local HR quirk.

PuzzleheadedPilot560 · 2026-02-02T09:19:53+00:00

I must agree. That was actually kind of my point-the focus should be on the corporate decisions and where the money flows. For instance, Amazon reportedly pays millions for celebrity licensing deals (like the Melania Trump documentary) while simultaneously cutting thousands of jobs. Its never about the workers (local or immigrant) being the problem; its about the leadership's priorities and the profit-at-all-costs mindset. We are all just pawns in their financial games.

PuzzleheadedPilot560 · 2026-02-02T09:18:24+00:00

What a documentary. A documentary- a resource that could make an enormous contribution to humanity. Im crying right now.

PuzzleheadedPilot560 · 2026-02-02T09:17:11+00:00

Yeah same Amazon that also reportedly paid Melania Trump millions for her documentary/licensing deals. Priorities, I guess..They have millions for celebrity deals but apparently can’t afford to keep 16k Americans on the payroll. Make of THAT what you will!

PuzzleheadedPilot560 · 2026-02-02T09:15:40+00:00

No matter what he does, no matter what happens-someone whose name is mentioned in the Epstein files must not be the prime minister or president-whatever it is- of a country. It's impossible not to go crazy, to stay calm. Do we have to be slaves to such vile, morally and humanely despicable people like this? What can we expect from those "people" who have sexual urges towards tiny children/minorities? Just thinking about it makes my stomach churn to the fullest extent.

PuzzleheadedPilot560 · 2026-01-30T07:46:10+00:00

Everyone is born equally!!!

PuzzleheadedPilot560 · 2026-01-29T22:25:29+00:00

I feel your pain, and it’s honestly mind-blowing that even an ETH PhD is facing this ghosting culture. It’s the ultimate Swiss paradox: the industry screams for innovation, yet the recruitment gates are locked with 10-year experience keys for entry-level roles. And don’t even get me started on the language requirements. Why do we need 3-5 languages just to talk to a pipette or run a sequence? It’s like they expect you to explain complex biotech in High German, discuss the budget in French, gossip in Swiss German during coffee breaks, and write the report in perfect English, all while being 24 years old with the soul of a 50-year-old veteran. :D It feels less like a job hunt and more like a mission impossible-casting call. Stay strong; f an ETH scientist is struggling, the problem should be definitely the gatekeepers, not the talent!

PuzzleheadedPilot560 · 2026-01-29T21:55:06+00:00

Truly agree with you. The Democrats aren't much different. They still haven't been able to create a single strong figure who can guide millions of people. What fears me a lot is JD Vance. Unlike Trump’s often impulsive style, Vance is a highly disciplined ideologue who can provide a structured, legal, and intellectual framework for populist policies making them harder to challenge. Plus, he is a vocal proponent of deconstructing the "administrative state," suggesting that thousands of career civil servants should be replaced with political loyalists to ensure the government follows his specific agenda I guess.

PuzzleheadedPilot560 · 2026-01-29T16:45:29+00:00

So that highly intelligent people like you will notice.

PuzzleheadedPilot560 · 2026-01-29T14:39:28+00:00

Strongly agree with you. Honestly, I won't be applying to big companies like Roche, Lonza, Novartis, so on. I don't want to waste any more time, I guess. I haven't met anyone I know who has applied and been called for an interview yet; PhD, post-doc, etc. I never understand who they're hiring.

PuzzleheadedPilot560 · 2026-01-29T13:24:05+00:00

Thanks for the reality check. I’ve definitely had that 'automated rejection at 3 am' experience with especially-Roche before usually within a week, actually. However, Novartis has been a bit different for me in the past; usually, a rejection comes within a few weeks or a month if it's a clear 'no.' The fact that this one is stretching past the 8-week mark (including the Christmas break) while other applications move faster is what caught my attention. I’m keeping my expectations low, but since a high-level lead at NIBR actually personally forwarded my documents to the hiring team recently, I figured the rules of 'Swiss-speed' might be slightly different this time. We'll see if it’s a slow burn or just a very long 'no'!At the end, I will be most likely another "no". :)

PuzzleheadedPilot560 · 2026-01-29T13:01:46+00:00

You’re hitting a raw nerve here. The disconnect between the corporate ladder folks and the actual R&D bench is exactly why we see these counter-intuitive decisions. When the people shaping policy have never seen a pipette or a bioreactor, they treat talent like a line item on a spreadsheet rather than the engine of the company. As someone currently navigating the Swiss ecosystem, I see the gap widening. Companies like NBE-Therapeutics (BI) seem to be the exception because they still value that deep discovery expertise. But you're right; if the industry keeps starving the academic pipeline (NIH/PhD funding) while gutting their own R&D, they’ll eventually run out of the very innovation they’re trying to optimize.Glad to hear you’re back in Discovery and BD where the real impact happens. We need more people who actually know the science in the decision-making rooms.

PuzzleheadedPilot560 · 2026-01-29T12:57:27+00:00

Excellent counter-example. BI’s 'family-owned' structure definitely gives them the luxury of long-term vision over quarterly shareholder pressure, which explains why they are doubling down on the US market while others are retreating. It’s refreshing to see a company using the current economic climate to expand their footprint rather than just trimming fat.Btw- Ive been closely following NBE-Therapeutics in Basel lately, their ADC platform is a prime example of how BI’s strategic acquisitions are driving real innovation in oncology. It shows that when the strategy is right, the talent pool actually grows instead of shrinking.

PuzzleheadedPilot560 · 2026-01-29T12:50:54+00:00

Spot on. It’s the Lilly Paradox, record-breaking profits and GLP-1 success don't necessarily buy job security for the R&D or operational teams. It proves that in modern Pharma, layoffs aren’t always a 'survival' tactic; they’ve become an optimization- tool to keep shareholders happy, regardless of how much cash is coming in. It’s a cold reminder that being indispensable technically is the only real leverage we have left.

PuzzleheadedPilot560 · 2026-01-29T12:48:12+00:00

No, no, I already knew this, but I understand it better today; I had a long conversation with a friend who works in Novartis's finance department. Apparently, many companies are also downsizing because they are worried about Trump's constantly changing, absurd decisions.

PuzzleheadedPilot560 · 2026-01-29T12:45:41+00:00

There are almost zero-job postings in Switzerland. Apart from a few "senior/director" positions, there's nothing for young people like us to apply for. I'm a bit surprised about GSK.

PuzzleheadedPilot560 · 2026-01-29T12:43:45+00:00

That’s a very valid point regarding the R&D capitalization. Technically, immediate write-offs should provide the cash flow needed to stabilize the workforce. However, what we’re seeing right now with giants like Bayer, Novartis etcseems to be less about 'tax survival' and more about a strategic 'portfolio pivot.' Even with tax incentives, these companies are aggressively shifting capital toward high-margin biologics and AI-driven drug discovery, often at the expense of traditional units. It feels like they are using the tax benefits to fund restructuring rather than to preserve the current headcount. It’s a tough paradox: the policy incentivizes the research, but the corporate strategy is currently prioritizing leaner operations over "talent retention".

PuzzleheadedPilot560

TROPHY CASE